MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE

Merck (MRK) is strategically mitigating the impending 2028 patent expiration of its top revenue driver, Keytruda, which accounts for approximately 50% of its pharmaceutical sales, by heavily investing in its newly launched pulmonary arterial hypertension (PAH) drug, Winrevair. Winrevair, approved in March 2024, has shown significant efficacy in Phase III trials, leading to early study cessations, and the FDA has granted priority review for a label update based on the ZENITH study, with a decision anticipated by October 25, 2025. While Winrevair generated $280 million in Q1 2025 and is projected for long-term growth, it faces substantial competition in the PAH market from companies like United Therapeutics and Johnson & Johnson, as Merck also pursues Keytruda lifecycle management through new combinations and a subcutaneous formulation.

Analysis

Merck (MRK) is navigating a critical strategic transition centered on mitigating the 2028 patent expiration of its blockbuster drug, Keytruda, which constitutes approximately 50% of its pharmaceutical sales. The primary pillar of this strategy is the recently launched pulmonary arterial hypertension (PAH) drug, Winrevair. Winrevair has demonstrated a compelling clinical profile, evidenced by multiple Phase III trials (ZENITH, HYPERION) being stopped early due to "overwhelming efficacy," and has already generated $280 million in sales in its first full quarter (Q1 2025). An upcoming FDA priority review decision on October 25, 2025, to update Winrevair's label could further bolster its market position. However, this growth narrative is tempered by significant competitive pressures in the PAH market from incumbents like Johnson & Johnson, whose PAH franchise posted $1.02 billion in Q1 2025 revenue, and United Therapeutics, with its leading drug Tyvaso generating $466.3 million. Financially, Merck's stock reflects this uncertainty, having underperformed its industry by a wide margin with a 17.1% year-to-date decline. Despite this, its valuation appears attractive, trading at a forward P/E of 8.84, substantially below both the industry average of 15.05 and its own 5-year mean, though slightly declining consensus earnings estimates for 2025 and 2026 suggest analyst caution.

Key Decisions for Investors

• Investors should closely monitor key upcoming catalysts, particularly the FDA's decision on the subcutaneous formulation of Keytruda in September and the Winrevair label update on October 25, 2025, as positive outcomes are critical to de-risking the post-2028 revenue outlook.
• Given the stock's significant underperformance and low forward P/E of 8.84, the current valuation may present a compelling entry point for long-term investors, but this must be weighed against the execution risk and slightly declining earnings estimates.
• It is crucial to track Winrevair's quarterly sales trajectory and market share gains against the established PAH franchises of Johnson & Johnson and United Therapeutics to validate its potential to meaningfully offset the anticipated revenue decline from Keytruda's loss of exclusivity.